secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001193125-25-082819
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Therapeutics enters new CEO employment agreement with severance benefits; CAO severance set
--------------------------------------------------------------------------------

- CEO Oxtoby's new base salary is $569,100; target bonus up to 55% of base salary.
- On non-CIC termination without cause/good reason: 12 months base salary plus COBRA.
- On CIC termination: 18 months base salary, 150% target bonus lump sum, 18 months COBRA, full equity acceleration.
- CAO Hagen gets 9 months base salary (non-CIC) or 12 months plus 100% target bonus lump sum (CIC) and equity acceleration.
- Both agreements require release and continued compliance with restrictive covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525082819/0001193125-25-082819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525082819/d949516d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-082819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer